Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands-Reference-Cited by-同舟云学术

Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands

Published:2018-06-22 Issue:9 Volume:21 Page:869-877
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Gherardi Alexandre¹,Roze Stéphane¹,Kuijvenhoven Johan²,Ghatnekar Ola³,Yip Sonderegger Yum Lina⁴

Affiliation:

1. HEVA HEOR, Lyon, France;

2. Spaarne Gasthuis, Haarlem Zuid, Haarlem, the Netherlands;

3. Ferring International PharmaScience Center, Copenhagen, Denmark;

4. Ferring International Center, St-Prex, Switzerland

Funder

Ferring Pharmaceuticals

HEVA-HEOR

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1484371

Reference68 articles.

1. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

2. The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United States

3. The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study

4. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

5. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD).

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling;PharmacoEconomics;2024-08-06

2. Formulation and optimization of a single-layer coat for targeting budesonide pellets to the descending Colon;Pharmaceutical Development and Technology;2024-03-06

3. Management and treatment optimization of patients with mild to moderate ulcerative colitis;Expert Review of Clinical Immunology;2023-12-07

4. A Fully Replicate, Cross-over, Bioequivalence Study to Compare Two Prolonged Release, Multi-matrix Tablet Formulations of Budesonide in Healthy Indian Adults;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2023

5. Different trends for preparation of budesonide pellets with enhanced dissolution rate;Advanced Powder Technology;2022-08